Administrative Supplements for P30 Cancer Centers Support Grants (CCSG) to Stimulate Research in HIV/AIDS Cancer Research Projects at NCI-Designated Cancer Centers
Release Date: January 18, 2024
Request Receipt Due: April 5, 2024
Earliest Anticipated Start Date for Awards: July 8, 2024
Purpose and Goals
The National Cancer Institute (NCI) announces an opportunity for supplemental funding in support of projects that utilize biospecimens from the AIDS and Cancer Specimen Resource (ACSR)* inventory (or another certified biorepository); data from existing cohorts; and/or biospecimens and clinical data from the cancer center itself, including international partnerships of the center. The primary goal of this initiative is to stimulate research in HIVassociated cancers. This effort is aimed to expand the knowledge base of HIV/AIDS cancer pathogenesis, etiology, early detection, treatments, and cures. It is intended that discoveries from this effort will inform and guide the development of novel diagnostic, preventive and therapeutic strategies for AIDS-defining and/or non-AIDS-defining cancers. The research proposal should address questions that can be tested by using biospecimens and/or cohort data.
Administrative Supplements for P30 Cancer Centers Support Grants (CCSG) to Stimulate Research in Immunotherapy and Tumor Microenvironment in HIV/AIDS Cancer Patients at NCI-Designated Cancer Centers
Release Date: January 18, 2024
Request Receipt Due: April 5, 2024
Earliest Anticipated Start Date for Awards: July 8, 2024
Purpose and Goals
The National Cancer Institute (NCI) announces an opportunity for supplemental funding to identify and advance immunotherapy translational approaches for HIV/AIDS individuals with cancer. To accomplish this advancement, new, more effective immune-based therapeutic regimens for people with HIV/AIDS-related cancers should be explored through:
• the discovery and characterization of immunotherapeutic targets,
• the development of new immunotherapy treatment approaches, and
• the improved understanding of the immunosuppressive tumor microenvironment
It will be extremely important that the applicant outlines specifically the HIV outcomes for the proposed work. Note that Kaposi’s sarcoma-associated herpesvirus (KSHV) studies that are proposed should be in the context of HIV (with HIV outcomes specified) with alignment at 100%. As such, if the NIH Office of AIDS Research (OAR) does not deem an application as 100% aligned, the NCI Office of Cancer Centers (OCC) will be unable to fund it.
Administrative Supplements for P30 Cancer Centers Support Grants (CCSG) to Stimulate Research in HIV-Associated Cancers in Aging Populations
Release Date: January 18, 2024
Request Receipt Due: April 5, 2024
Earliest Anticipated Start Date for Awards: July 8, 2024
Purpose & Goals
The National Cancer Institute (NCI) announces an opportunity for supplemental funding to advance the understanding of the interface between aging and cancer among people living with HIV (PWH). These supplements are intended to encourage the development of interdisciplinary research teams, establish appropriate research infrastructure, and support exploratory projects seeking to better understand the role of aging in PWH with cancer